Search research articles
Contact Us
Filters
Showing results (1-10 of 121) with videos related to
Page
of 13
Sort By:
Cardiovascular & Hematological Disorders Drug Targets
|
March 24, 2007
Novel insights into Lp(a) physiology and pathogenicity: more questions than answers?
Marlys L Koschinsky
Current Atherosclerosis Reports
|
August 18, 2005
Lipoprotein(a) and atherosclerosis: new perspectives on the mechanism of action of an enigmatic lipoprotein
Marlys L Koschinsky
The Canadian Journal of Cardiology
|
August 17, 2004
Lipoprotein(a) and the link between atherosclerosis and thrombosis
Marlys L Koschinsky
Atherosclerosis
|
May 23, 2022
The long journey of lipoprotein(a) from cardiovascular curiosity to therapeutic target
Marlys L Koschinsky, Florian Kronenberg
Current Opinion in Lipidology
|
October 3, 2019
Proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease: more than meets the eye?
Michael B Boffa, Marlys L Koschinsky
Atherosclerosis
|
May 23, 2022
Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiology
Marlys L Koschinsky, Michael B Boffa
Journal of Clinical Lipidology
|
May 14, 2026
It's time to test all adults for lipoprotein(a)
Michael J Wilkinson, Marlys L Koschinsky
The Biochemical Journal
|
September 20, 2024
Lipoprotein(a) and cardiovascular disease
Michael B Boffa, Marlys L Koschinsky
Current Opinion in Lipidology
|
March 17, 2004
Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity
Marlys L Koschinsky, Santica M Marcovina
Clinical Biochemistry
|
March 3, 2007
Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles
Michael B Boffa, Marlys L Koschinsky
Page
of 13
Search research articles
Search
Showing results (1-10 of 121) with videos related to
Sort By:
Page
of 13
Cardiovascular & Hematological Disorders Drug Targets
|
March 24, 2007
Novel insights into Lp(a) physiology and pathogenicity: more questions than answers?
Marlys L Koschinsky
Current Atherosclerosis Reports
|
August 18, 2005
Lipoprotein(a) and atherosclerosis: new perspectives on the mechanism of action of an enigmatic lipoprotein
Marlys L Koschinsky
The Canadian Journal of Cardiology
|
August 17, 2004
Lipoprotein(a) and the link between atherosclerosis and thrombosis
Marlys L Koschinsky
Atherosclerosis
|
May 23, 2022
The long journey of lipoprotein(a) from cardiovascular curiosity to therapeutic target
Marlys L Koschinsky, Florian Kronenberg
Current Opinion in Lipidology
|
October 3, 2019
Proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease: more than meets the eye?
Michael B Boffa, Marlys L Koschinsky
Atherosclerosis
|
May 23, 2022
Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiology
Marlys L Koschinsky, Michael B Boffa
Journal of Clinical Lipidology
|
May 14, 2026
It's time to test all adults for lipoprotein(a)
Michael J Wilkinson, Marlys L Koschinsky
The Biochemical Journal
|
September 20, 2024
Lipoprotein(a) and cardiovascular disease
Michael B Boffa, Marlys L Koschinsky
Current Opinion in Lipidology
|
March 17, 2004
Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity
Marlys L Koschinsky, Santica M Marcovina
Clinical Biochemistry
|
March 3, 2007
Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles
Michael B Boffa, Marlys L Koschinsky
Page
of 13